

SEED

Intellectual Property Law Group PLLC

**RECEIVED
CENTRAL FAX CENTER**

NOV 19 2003

701 Fifth Avenue, Suite 6300
Seattle WA 98104-7092 USA
Facsimile: (206) 682-6031
Telephone: (206) 622-4900
www.seedlaw.com

November 19, 2003

OFFICIALCarol D. Laherty, Ph.D.
caroll@seedlaw.com**Facsimile Transmission**12 pages including this page**TO: EXAMINER: Gollamudi S. Kishore**
ART UNIT: 1615
Fax No.: 703-872-9306**RE: U.S. Patent Application No. 09/896,812**
LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF
Attorney Docket No.: 480208.408☐ Urgent ☐ For Review ☒ Please Confirm Receipt ☐ Please Reply ASAP**Comments:**

PLEASE DELIVER IMMEDIATELY
TO
EXAMINER: GOLLAMUDI S. KISHORE
ART UNIT: 1615


If you do not receive all pages, please call John T. Oliver at (206) 622-4900 or fax our office.


Transmission Information: Date _____ Time _____ By _____

CONFIDENTIALITY NOTICE: The information contained in this facsimile message is legally privileged and/or confidential information intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any use, dissemination, distribution, or copying of this facsimile or its content is strictly prohibited. If you have received this facsimile in error, please immediately notify us by telephone and return the original facsimile message to us by mail or destroy it without making a copy. Thank you.

TRANSMITTAL FORM (To be used for all correspondence after initial filing)	Application Number	09/896,812
	Filing Date	June 29, 2001
	First Named Inventor	Thomas D. Madden
	Art Unit	1815
	Examiner Name	Gollamudi S. Kishore
	Attorney Docket No.	480208.408

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement; Form PTO-1449 <input type="checkbox"/> Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Individual Name	Carol D. Laherty, Ph.D.	Customer Number 00500
Signature		
Date	November 19, 2003	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO at 703-872-9306 on the date shown below.		
Typed or printed name	John T. Oliver	
Signature		Date: November 19, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. C:\N\PartB\Manage\UOI\NOV434597_1.DOC

PATENT

I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

11/19/03
Date

John T. Oliver
John T. Oliver

RECEIVED
CENTRAL FAX CENTER

NOV 19 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Thomas D. Madden et al.
Application No. : 09/896,812
Filed : June 29, 2001
For : LIPOSOMAL ANTINEOPLASTIC DRUGS AND USES THEREOF

OFFICIAL

Examiner : Gollamudi S. Kishore
Art Unit : 1615
Docket No. : 480208.408
Date : November 19, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL AMENDMENT

Commissioner for Patents:

By way of supplemental response to the Office Action dated April 9, 2003, please amend the application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 11 of this paper.